GLP-1 medications like Ozempic, Wegovy, and Mounjaro have been some of the most talked-about drugs in healthcare over the last few years, and Medicare’s approach to covering them has been shifting almost as fast as the headlines. If you looked into this a year or two ago and came away confused, it’s worth another look — the coverage landscape in 2026 isn’t the same as it was.
We’ve covered the basics of GLP-1 coverage and the GLP-1 Bridge Program in earlier posts, so this one focuses specifically on what’s changed and what’s still evolving heading into 2026.
The Coverage Line Has Always Been About the “Why,” Not the Drug
Medicare Part D has never covered GLP-1 medications for weight loss alone — that restriction goes back to a long-standing exclusion on drugs used purely for weight management. What’s changed is how many approved uses now exist around that line. As GLP-1 drugs have received additional FDA approvals for conditions like cardiovascular risk reduction, sleep apnea, and kidney disease in patients with type 2 diabetes, more Part D plans have formulary pathways to cover the same medication when it’s prescribed for one of those approved conditions rather than weight loss on its own.
In practice, this means two people taking the same drug, at the same dose, can have very different coverage outcomes depending on the diagnosis code attached to the prescription. That distinction matters more now than it did even a year ago, because there are more approved conditions to potentially qualify under.
Prior Authorization Has Gotten More Detailed, Not Less
As coverage pathways have expanded, so has the documentation plans want to see. Expect prior authorization requests to ask for more specific clinical history in 2026 — things like documented cardiovascular risk factors, prior treatment attempts, or specific lab values — rather than a general “medically necessary” note. This is partly a cost-control response to how expensive and high-demand these medications have become, and partly plans catching up to the more complex web of approved uses.
Formulary Tiers Keep Shifting
Because GLP-1 drugs are among the most expensive medications many Part D plans cover, formulary placement has been unusually active. Plans move these drugs between tiers, adjust prior authorization criteria, and update step therapy requirements more frequently than they do for most other drug classes. If you’re on one of these medications, it’s worth checking your plan’s formulary at the start of the year and again mid-year rather than assuming your coverage from January still applies in July.
The Part D Out-of-Pocket Cap Changes the Math
One of the more significant shifts affecting anyone on an expensive medication like a GLP-1 drug is the Part D out-of-pocket cap, which is $2,100 for 2026. Once your covered drug costs hit that cap, you owe nothing more for covered Part D drugs for the rest of the calendar year. For someone on a GLP-1 medication with a high monthly cost, reaching that cap can happen faster than it would with less expensive drugs — which changes the year-over-year cost picture in a way that didn’t exist before this cap structure was introduced.
What This Means If You’re Considering a GLP-1 Medication
If your doctor has discussed a GLP-1 medication with you, a few things are worth doing before you fill the first prescription:
- Confirm the specific diagnosis code being used and whether it aligns with an approved coverage pathway on your plan’s formulary.
- Ask your plan directly what prior authorization documentation they require — don’t rely on secondhand information from a pharmacy counter conversation.
- Check where the drug sits on your plan’s tier list, since this affects your cost even after you clear any deductible (up to $615 for 2026).
- Factor in the $2,100 out-of-pocket cap when estimating your total annual cost, since it may arrive sooner than expected on a higher-cost medication.
If coverage for a specific medication is a major factor in choosing a plan, that’s exactly the kind of detail worth reviewing during a plan comparison — our medicare plans page is a good place to start, and you can always schedule time to go through your specific medication list with an agent.
Bottom Line
GLP-1 coverage under Medicare isn’t static, and 2026 has brought more nuance — not less — as approved uses expand and plans adjust their formularies in response. The safest approach is to treat your coverage as something to re-check periodically, not something you confirmed once and can forget about.
Price Services Group, LLC is not affiliated with or endorsed by the U.S. government or the federal Medicare program. NPN: 18530055 | Agency NPN: 20387435
Have questions? Schedule a free review with Kayla Price, a licensed insurance agent at Price Services Group. Call 866-648-1578 or visit priceservicesgroup.com/schedule.